Il y a eu 50 transactions d'initiés récentes enregistrées pour Day One Biopharmaceuticals, Inc. (DAWN), dont 14 achats et 33 ventes. Le total des achats d'initiés s'élève à RSU Award et le total des ventes d'initiés à $5.41M.
Les initiés notables ayant une activité récente comprennent York Charles N Ii, Vasconcelles Michael, Dubow Adam. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — DAWN
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-02-17 |
York Charles N Ii |
COO and CFO |
Vente Informative |
6,065 |
$11.60 |
$70.36K |
312,025 |
| 2026-02-17 |
Vasconcelles Michael |
Head of Research and Dev. |
Vente Informative |
2,728 |
$11.60 |
$31.65K |
4,397 |
| 2026-02-17 |
Dubow Adam |
Gen Counsel & Secretary |
Vente Informative |
6,395 |
$11.60 |
$74.19K |
72,694 |
| 2026-02-17 |
Merendino Lauren |
Chief Commercial Officer |
Vente Informative |
5,814 |
$11.60 |
$67.45K |
60,157 |
| 2026-02-17 |
Bender Jeremy |
Chief Executive Officer |
Vente Informative |
15,459 |
$11.60 |
$179.34K |
204,603 |
| 2026-02-15 |
York Charles N Ii |
COO and CFO |
Exercice d'Options (Vente) |
2,250 |
- |
- |
6,750 |
| 2026-02-15 |
Vasconcelles Michael |
Head of Research and Dev. |
Exercice d'Options |
7,125 |
- |
- |
7,125 |
| 2026-02-15 |
Dubow Adam |
Gen Counsel & Secretary |
Exercice d'Options (Vente) |
1,750 |
- |
- |
5,250 |
| 2026-02-15 |
Merendino Lauren |
Chief Commercial Officer |
Exercice d'Options (Vente) |
3,162 |
- |
- |
18,978 |
| 2026-02-15 |
Bender Jeremy |
Chief Executive Officer |
Exercice d'Options (Vente) |
4,750 |
- |
- |
14,250 |
| 2026-01-30 |
York Charles N Ii |
COO and CFO |
Attribution de RSU |
126,000 |
- |
- |
126,000 |
| 2026-01-30 |
Vasconcelles Michael |
Head of Research and Dev. |
Attribution de RSU |
114,000 |
- |
- |
114,000 |
| 2026-01-30 |
Dubow Adam |
Gen Counsel & Secretary |
Attribution de RSU |
70,000 |
- |
- |
70,000 |
| 2026-01-30 |
Merendino Lauren |
Chief Commercial Officer |
Attribution de RSU |
74,000 |
- |
- |
74,000 |
| 2026-01-30 |
Bender Jeremy |
Chief Executive Officer |
Attribution de RSU |
237,000 |
- |
- |
237,000 |
| 2025-11-25 |
Bender Jeremy |
Chief Executive Officer |
Don (Donné) |
7,225 |
- |
- |
- |
| 2025-11-17 |
York Charles N Ii |
COO and CFO |
Vente Informative |
4,062 |
$8.91 |
$36.21K |
294,715 |
| 2025-11-17 |
Dubow Adam |
Gen Counsel & Secretary |
Vente Informative |
4,319 |
$8.91 |
$38.5K |
62,626 |
| 2025-11-17 |
Merendino Lauren |
Chief Commercial Officer |
Vente Informative |
3,726 |
$8.91 |
$33.22K |
50,809 |
| 2025-11-17 |
Bender Jeremy |
Chief Executive Officer |
Vente Informative |
15,894 |
$8.91 |
$141.69K |
177,165 |
| 2025-11-15 |
York Charles N Ii |
COO and CFO |
Exercice d'Options (Vente) |
1,375 |
- |
- |
- |
| 2025-11-15 |
Dubow Adam |
Gen Counsel & Secretary |
Exercice d'Options (Vente) |
1,750 |
- |
- |
7,000 |
| 2025-11-15 |
Merendino Lauren |
Chief Commercial Officer |
Exercice d'Options (Vente) |
3,162 |
- |
- |
22,140 |
| 2025-11-15 |
Bender Jeremy |
Chief Executive Officer |
Exercice d'Options (Vente) |
3,570 |
- |
- |
- |
| 2025-11-06 |
Dable Habib J |
Director |
Restitution d'Actions |
66,660 |
$13.81 |
$920.57K |
- |
| 2025-11-06 |
Bender Jeremy |
Chief Executive Officer |
Restitution d'Actions |
286,000 |
$11.87 |
$3.39M |
- |
| 2025-06-16 |
Vasconcelles Michael |
Officer |
Inconnu |
- |
- |
- |
- |
| 2025-06-16 |
Vasconcelles Michael |
Head of Research and Dev. |
Attribution de RSU |
226,000 |
- |
- |
226,000 |
| 2025-06-02 |
Garland J. Scott |
Director |
Attribution de RSU |
15,000 |
- |
- |
15,000 |
| 2025-06-02 |
Ramasastry Saira |
Director |
Attribution de RSU |
15,000 |
- |
- |
15,000 |
| 2025-06-02 |
Holles Natalie C. |
Director |
Attribution de RSU |
15,000 |
- |
- |
15,000 |
| 2025-06-02 |
Nicholson Garry A |
Director |
Attribution de RSU |
15,000 |
- |
- |
15,000 |
| 2025-06-02 |
Dable Habib J |
Director |
Attribution de RSU |
15,000 |
- |
- |
15,000 |
| 2025-06-02 |
Grossman William |
Director |
Attribution de RSU |
15,000 |
- |
- |
15,000 |
| 2025-06-02 |
Josey John A. |
Director |
Attribution de RSU |
15,000 |
- |
- |
15,000 |
| 2025-05-16 |
York Charles N Ii |
COO, CFO and Secretary |
Vente Informative |
4,282 |
$6.26 |
$26.8K |
265,231 |
| 2025-05-16 |
Dubow Adam |
General Counsel |
Vente Informative |
4,552 |
$6.26 |
$28.49K |
47,136 |
| 2025-05-16 |
Merendino Lauren |
Chief Commercial Officer |
Vente Informative |
3,927 |
$6.26 |
$24.57K |
35,161 |
| 2025-05-16 |
Bender Jeremy |
Chief Executive Officer |
Vente Informative |
13,964 |
$6.26 |
$87.39K |
145,737 |
| 2025-05-15 |
York Charles N Ii |
COO, CFO and Secretary |
Exercice d'Options (Vente) |
1,375 |
- |
- |
2,750 |
| 2025-05-15 |
Dubow Adam |
General Counsel |
Exercice d'Options (Vente) |
1,750 |
- |
- |
10,500 |
| 2025-05-15 |
Merendino Lauren |
Chief Commercial Officer |
Exercice d'Options (Vente) |
3,162 |
- |
- |
28,464 |
| 2025-05-15 |
Bender Jeremy |
Chief Executive Officer |
Exercice d'Options (Vente) |
3,562 |
- |
- |
7,132 |
| 2025-02-26 |
Merendino Lauren |
Chief Commercial Officer |
Inconnu |
55,313 |
- |
- |
- |
| 2025-02-18 |
York Charles N Ii |
COO, CFO and Secretary |
Vente Informative |
4,370 |
$11.96 |
$52.28K |
252,638 |
| 2025-02-18 |
Dubow Adam |
General Counsel |
Vente Informative |
4,646 |
$11.96 |
$55.58K |
39,602 |
| 2025-02-18 |
Bender Jeremy |
Chief Executive Officer |
Vente Informative |
12,048 |
$11.96 |
$144.13K |
128,015 |
| 2025-02-15 |
York Charles N Ii |
COO, CFO and Secretary |
Exercice d'Options (Vente) |
1,375 |
- |
- |
4,125 |
| 2025-02-15 |
Dubow Adam |
General Counsel |
Exercice d'Options (Vente) |
1,750 |
- |
- |
12,250 |
| 2025-02-15 |
Bender Jeremy |
Chief Executive Officer |
Exercice d'Options (Vente) |
3,562 |
- |
- |
10,694 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
